University of Texas at Austin

ReCode Therapeutics , on track with its plan to take its two lead programs into the clinic this year, announced on 19 September that it raised another $50m in series B venture capital, bringing the ro

Lysogene Licenses Gene Therapy Candidate From Yeda Research Advancing a collaboration inked in July 2020, gene therapy specialist Lysogene SA said on 12 April that it is taking its option to license